ACTH 1-39: Dosage, Protocol, and Research Guide
Adrenocorticotropic hormone for adrenal stimulation and immune modulation
Mechanism
Stimulates adrenal cortex to produce cortisol and other corticosteroids, has direct anti-inflammatory effects
Protocol at a glance
| Starting dose | 0.25mg |
|---|---|
| Maintenance dose | 0.25mg |
| Maximum dose | 0.5mg |
| Frequency | Twice weekly |
| Typical duration | 4-8 weeks |
| Route | Subcutaneous/IM |
| Injection site | Abdomen or glute |
| Timing | Morning |
Side effects
- Fluid retention
- Mood changes
- Glucose elevation
Contraindications
- Systemic fungal infections
- Recent live vaccines
Protocol notes
- Stimulates natural cortisol
- Anti-inflammatory effects
- Monitor glucose and BP
- May help with MS
- Short-term use recommended
Frequently asked questions
Is ACTH 1-39 legal?
The legal status of ACTH 1-39 varies by jurisdiction and formulation. Clinical forms with FDA approval exist for specific medical conditions, while ACTH 1-39 as a research compound may fall outside standard regulatory frameworks depending on regional laws. Individuals should verify local regulations and consult with legal counsel before procurement or use.
How should I cycle ACTH 1-39?
Standard research protocols for ACTH 1-39 run for 4-8 weeks, reflecting short-term use recommendations. Typical cycling involves twice-weekly dosing at 0.25 mg (maintenance dose, with a maximum of 0.5 mg per dose). After a cycle concludes, an off-cycle period allows adrenal function to normalize and reduces cumulative glucocorticoid effects. Specific cycle design and timing should be determined in consultation with a qualified healthcare provider.
Can I stack ACTH 1-39 with other peptides?
Research on stacking ACTH 1-39 with other peptides remains limited. Because ACTH 1-39 operates through endocrine and immune pathways, combining it with other immunomodulatory or endocrine-active peptides could produce additive or unpredictable effects. Any stacking protocol should be designed and supervised by a healthcare provider with expertise in peptide pharmacology and endocrine interactions.
What does ACTH 1-39 feel like?
Documented side effects of ACTH 1-39 include mood changes, fluid retention, and glucose elevation. Mood changes can include altered emotional state and affect due to cortisol elevation. Fluid retention commonly manifests as bloating or weight gain. Glucose elevation may be associated with increased thirst or fatigue. Individual experiences vary widely based on baseline health status and sensitivity to cortisol-related effects.
What lab work should I monitor while using ACTH 1-39?
Critical monitoring parameters include blood glucose and blood pressure, as ACTH 1-39 can elevate both through cortisol stimulation. A comprehensive metabolic panel (CMP) tracking glucose, electrolytes, and kidney function is recommended. Cortisol levels may be measured to confirm the peptide's endocrine effect. Depending on research context, immune markers or inflammatory markers may also be tracked. All monitoring should occur under medical supervision.
What is the correct dosage for ACTH 1-39?
Standard research dosing for ACTH 1-39 is as follows: starting dose 0.25 mg, maintenance dose 0.25 mg, administered twice weekly via subcutaneous or intramuscular injection (in the abdomen or glutes), in the morning. The maximum single dose is 0.5 mg. Protocols typically run for 4-8 weeks. Individual adjustments should only be made under medical supervision based on individual response and tolerance.
What are the side effects of ACTH 1-39?
Documented side effects of ACTH 1-39 include fluid retention, mood changes, and glucose elevation. Fluid retention may manifest as bloating, weight gain, or edema. Mood changes can include altered affect, anxiety, or emotional shifts related to cortisol elevation. Glucose elevation reflects cortisol's metabolic effects and requires monitoring, particularly in those with metabolic risk factors. ACTH 1-39 is contraindicated in systemic fungal infections and following recent live vaccines. Report any concerning effects to a healthcare provider immediately.
Can ACTH 1-39 help with autoimmune conditions like multiple sclerosis?
Preliminary research suggests ACTH 1-39 may have potential in autoimmune disease states, particularly multiple sclerosis (MS), due to its anti-inflammatory and immunomodulatory effects. The peptide stimulates endogenous cortisol production while exerting direct anti-inflammatory activity, providing theoretical rationale for immune modulation. Clinical evidence in autoimmune conditions remains limited; however, FDA-approved ACTH formulations have documented evidence in specific conditions (PMID 37397803). Any use for autoimmune disease requires close medical supervision and should be based on individual clinical assessment.
More Immune & Inflammation peptides · All peptide guides · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.